- · 《环渤海经济瞭望》栏目[05/29]
- · 《环渤海经济瞭望》数据[05/29]
- · 《环渤海经济瞭望》收稿[05/29]
- · 《环渤海经济瞭望》投稿[05/29]
- · 《环渤海经济瞭望》征稿[05/29]
- · 《环渤海经济瞭望》刊物[05/29]
一、来稿必须是作者独立取得的原创性学术研究成果，来稿的文字复制比（相似度或重复率）必须低于用稿标准，引用部分文字的要在参考文献中注明；署名和作者单位无误，未曾以任何形式用任何文种在国内外公开发表过；未一稿多投。 二、来稿除文中特别加以标注和致谢之外，不侵犯任何版权或损害第三方的任何其他权利。如果20天后未收到本刊的录用通知，可自行处理(双方另有约定的除外)。 三、来稿经审阅通过，编辑部会将修改意见反馈给您，您应在收到通知7天内提交修改稿。作者享有引用和复制该文的权利及著作权法的其它权利。 四、一般来说，4500字（电脑WORD统计，图表另计）以下的文章，不能说清问题，很难保证学术质量，本刊恕不受理。 五、论文格式及要素：标题、作者、工作单位全称(院系处室)、摘要、关键词、正文、注释、参考文献(遵从国家标准：GB\T7714-2005，点击查看参考文献格式示例)、作者简介(100字内)、联系方式(通信地址、邮编、电话、电子信箱)。 六、处理流程：（1） 通过电子邮件将稿件发到我刊唯一投稿信箱（2）我刊初审周期为2－3个工作日，请在投稿3天后查看您的邮箱，收阅我们的审稿回复或用稿通知；若30天内没有收到我们的回复，稿件可自行处理。（3）按用稿通知上的要求办理相关手续后，稿件将进入出版程序。（4） 杂志出刊后，我们会按照您提供的地址免费奉寄样刊。 七、凡向文教资料杂志社投稿者均被视为接受如下声明：（1）稿件必须是作者本人独立完成的，属原创作品（包括翻译），杜绝抄袭行为，严禁学术腐败现象，严格学术不端检测，如发现系抄袭作品并由此引起的一切责任均由作者本人承担，本刊不承担任何民事连带责任。（2）本刊发表的所有文章，除另有说明外，只代表作者本人的观点，不代表本刊观点。由此引发的任何纠纷和争议本刊不受任何牵连。（3）本刊拥有自主编辑权，但仅限于不违背作者原意的技术性调整。如必须进行重大改动的，编辑部有义务告知作者，或由作者授权编辑修改，或提出意见由作者自己修改。（4）作品在《文教资料》发表后，作者同意其电子版同时发布在文教资料杂志社官方网上。（5）作者同意将其拥有的对其论文的汇编权、翻译权、印刷版和电子版的复制权、网络传播权、发行权等权利在世界范围内无限期转让给《文教资料》杂志社。本刊在与国内外文献数据库或检索系统进行交流合作时，不再征询作者意见，并且不再支付稿酬。 九、特别欢迎用电子文档投稿，或邮寄编辑部,勿邮寄私人，以免延误稿件处理时间。
Stem cells: a new strategy for treatment of(4)
作者:网站采编关键词:
摘要：[3] Chang CY, Lin HJ, Li BR, et al.A novel metallo-βlactamase involved in the ampicillin resistance of Streptococcus pneumoniae ATCC 49 136 strain[J].PLoS One, 2016, 11(5):e0. [4] Huang S, Liu X, Lao
[3] Chang CY, Lin HJ, Li BR, et al.A novel metallo-βlactamase involved in the ampicillin resistance of Streptococcus pneumoniae ATCC 49 136 strain[J].PLoS One, 2016, 11(5):e0.
[4] Huang S, Liu X, Lao W, et distribution and antibiotic resistance of Streptococcus pneumoniae isolates collected at a Chinese hospital from 2011 to 2013[J].BMC Infect Dis, 2015, 15:312.
[5] Olesen B, Juhl-J?rgensen A, Tronier S, et al.A new successful approach to combating vancomycin-resistant enterococcus[J].J Hosp Infect, 2015, 91(4):375-376.
[6] Barber KE, Smith JR, Raut A, et of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid[J].J Antimicrob Chemother, 2016, 71(1):152-155.
[7] Du H, Chen L, Tang YW, et of the mcr-1 colistin resistance gene in carbapenem-resistant Enterobacteriaceae[J].Lancet Infect Dis, 2016, 16(3):287-288.
[8] Moxon CA, Paulus in Enterobacteriaceae infections in children[J].J Infect, 2016, 72(Suppl):S41-S49.
[9] Khong WX, Xia E, Marimuthu K, et al.Local transmission and global dissemination of New Delhi Metallo-Beta-Lactamase (NDM): a whole genome analysis[J].BMC Genomics, 2016, 17:452.
[10] Tada T, Miyoshi-Akiyama T, Shimada K, et and IMP-44 metallo-β-lactamases with increased carbapenemase activities in multidrug-resistant Pseudomonas aeruginosa[J].Antimicrob Agents Chemother, 2013, 57(9):4427-4432.
[11] Ghasemi F, Jalal action of zinc oxide nanoparticles in combination with ciprofloxacin and ceftazidime against multidrug-resistant Acinetobacter baumannii[J].J Glob Antimicrob Resist, 2016, 6:118-122.
[12] Tada T, Miyoshi-Akiyama T, Dahal RK, et of a novel 6’-N-aminoglycoside acetyltransferase, AAC(6’)-Iak, from a multidrug-resistant clinical isolate of Stenotrophomonas maltophilia[J].Antimicrob Agents Chemother, 2014, 58(10):6324-6327.
[13] Hajian B, Scocchera E, Keshipeddy S, et antifolates are potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis[J].PLoS One, 2016, 11(8):e0.
[14] Georghiou SB, Seifert M, Lin SY, et light on the performance of a pyrosequencing assay for drugresistant tuberculosis diagnosis[J].BMC Infect Dis, 2016,16(1):458.
[15] Gerlich MG, Piegsa J, Sch?fer C, et hospital hygiene to reduce the impact of multidrug-resistant organisms in health care--a prospective controlled multicenter study[J].BMC Infect Dis, 2015, 15:441.
[16] Rogers BA, Aminzadeh Z, Hayashi Y, et transfer of patients and the risk of multi-resistant bacterial infection[J].Clin Infect Dis, 2011, 53(1):49-56.
[17] Magiorakos AP, Srinivasan A, Carey RB, et , extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance[J].Clin Microbiol Infect, 2012, 18(3):268-281.
[18] Zumla A, Raviglione M, Hafner R, et [J].N Engl J Med, 2013, 368(8):745-755.
[19] Kalokhe AS, Shafiq M, Lee JC, et tuberculosis drug susceptibility and molecular diagnostic testing[J].Am J Med Sci, 2013, 345(2):143-148.
[20] Goldberg DE, Siliciano RF, Jacobs evolution: fi ghting drug-resistant TB, malaria, and HIV[J].Cell, 2012, 148(6):1271-1283.
[21] Wright J, Paauw of antibiotic therapy[J].Med Clin North Am, 2013, 97(4):667-679.
[22] Sundaram V, Kowdley of chronic hepatitis B infection[J].BMJ, 2015, 351:h4263.
[23] Kim SS, Cho SW, Kim SO, et hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy[J].J Med Virol,2013, 85(1):55-64.
[24] Uyeki TM, Cox concerns regarding novel influenza A (H7N9) virus infections[J].N Engl J Med,2013, 368(20):1862-1864.
[25] Mlakar J, Korva M, Tul N, et al.Zika virus associated with microcephaly[J].N Engl J Med, 2016, 374(10):951-958.
[26] WHO Ebola Response virus disease in West Africa--the first 9 months of the epidemic and forward projections[J].N Engl J Med, 2014, 371(16):1481-1495.
[27] Zyoud research trends of Middle East respiratory syndrome coronavirus: a bibliometric analysis[J].BMC Infect Dis, 2016, 16:255.
[28] Bose biology: a biologist’s viewpoint[J].Prog Biophys Mol Biol, 2013, 113(3):358-368.
[29] Hochberg J, Khaled S, Forman SJ, et for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in fi rst complete remission[J].Br J Haematol, 2013, 161(1):27-42.
[30] Moyé LA, Simari RD, Skarlatos SI.Bone marrow-derived cell therapy after myocardial infarction[J].JAMA, 2013,309(14):1459.
[31] Harn HJ, Lin SZ, Hung SH, et stem cells can abrogate chemical-induced liver fibrosis and facilitate recovery of liver function[J].Cell Transplant,2012, 21(12):2753-2764.
[32] Bennet L, Tan S, Van den Heuij L, et al.Cell therapy for neonatal hypoxia-ischemia and cerebral palsy[J].Ann Neurol, 2012, 71(5):589-600.
[33] Wilson JG, Liu KD, Zhuo H, et stem(stromal) cells for treatment of ARDS: a phase 1 clinical trial[J].Lancet Respir Med, 2015, 3(1):24-32.
文章来源：《环渤海经济瞭望》 网址: http://www.hbhjjw.cn/qikandaodu/2021/0115/449.html